Skip to content
The Policy VaultThe Policy Vault

vancomycinCareFirst (Caremark)

oral vancomycin for treatment of C. difficile associated diarrhea

Initial criteria

  • Requested drug will NOT be used intranasally or in a footbath
  • Requested drug is being prescribed for an FDA-approved indication or an indication supported in the compendia of current literature (AHFS, Micromedex, current accepted guidelines)
  • Infection is proven or strongly suspected to be caused by susceptible microorganisms
  • Patient cannot be treated with oral therapy OR request is for oral vancomycin for the treatment of C. difficile associated diarrhea or staphylococcal enterocolitis

Approval duration

serious, chronic, recurring infection: 12 months; other indications: 3 months